Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

Pharmacokinetics of Psilocybin in Normal Adult Volunteers

To see complete record on, please visit this link

Id: NCT02163707

Organisation Name: University of Wisconsin, Madison

Overal Status: Completed

Start Date: June 2014

Last Update: April 15, 2020

Lead Sponsor: University of Wisconsin, Madison

Brief Summary: Psilocybin is a naturally occurring psychedelic compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms. Psilocybin (4-phosphoroyloxy-N,N-dimethyltryptamine) is a hallucinogenic tryptamine that was first isolated from Psilocybe mushrooms in 1957. The objective of this Phase I clinical trial is to determine the pharmacokinetics of oral doses of psilocybin in normal, healthy adults. The study is performed in support of Phase II and Phase III studies of psilocybin for the treatment of refractory anxiety associated with incurable cancer, as well as other possible indications. Psilocybin is at present not an FDA-approved drug.

  • Healthy

Total execution time in seconds: 0.21517086029053